JP2022543765A5 - - Google Patents

Info

Publication number
JP2022543765A5
JP2022543765A5 JP2022506056A JP2022506056A JP2022543765A5 JP 2022543765 A5 JP2022543765 A5 JP 2022543765A5 JP 2022506056 A JP2022506056 A JP 2022506056A JP 2022506056 A JP2022506056 A JP 2022506056A JP 2022543765 A5 JP2022543765 A5 JP 2022543765A5
Authority
JP
Japan
Prior art keywords
cancer
conjugate
tumor
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022506056A
Other languages
English (en)
Japanese (ja)
Other versions
JP7627259B2 (ja
JP2022543765A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/043999 external-priority patent/WO2021021882A1/en
Publication of JP2022543765A publication Critical patent/JP2022543765A/ja
Publication of JP2022543765A5 publication Critical patent/JP2022543765A5/ja
Application granted granted Critical
Publication of JP7627259B2 publication Critical patent/JP7627259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022506056A 2019-07-30 2020-07-29 抗cd25抗体-フタロシアニン色素コンジュゲートおよび抗pd1抗体を使用したがんの処置のための近赤外(nir)光免疫療法(pit) Active JP7627259B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962880514P 2019-07-30 2019-07-30
US62/880,514 2019-07-30
US201962896453P 2019-09-05 2019-09-05
US62/896,453 2019-09-05
US201962931405P 2019-11-06 2019-11-06
US62/931,405 2019-11-06
PCT/US2020/043999 WO2021021882A1 (en) 2019-07-30 2020-07-29 Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antybody-phthalocyanine dye conjugate and anti-pd1 antibody

Publications (3)

Publication Number Publication Date
JP2022543765A JP2022543765A (ja) 2022-10-14
JP2022543765A5 true JP2022543765A5 (cg-RX-API-DMAC10.html) 2023-08-04
JP7627259B2 JP7627259B2 (ja) 2025-02-05

Family

ID=72047165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506056A Active JP7627259B2 (ja) 2019-07-30 2020-07-29 抗cd25抗体-フタロシアニン色素コンジュゲートおよび抗pd1抗体を使用したがんの処置のための近赤外(nir)光免疫療法(pit)

Country Status (6)

Country Link
US (1) US20220313822A1 (cg-RX-API-DMAC10.html)
EP (1) EP4004048A1 (cg-RX-API-DMAC10.html)
JP (1) JP7627259B2 (cg-RX-API-DMAC10.html)
CN (1) CN114423453A (cg-RX-API-DMAC10.html)
TW (1) TW202118518A (cg-RX-API-DMAC10.html)
WO (1) WO2021021882A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992591T3 (en) 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
ES2999358T3 (en) 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
US12704501B2 (en) 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
EP4069300A1 (en) * 2019-12-06 2022-10-12 Rakuten Medical, Inc. Methods for enhancing immunity and tumor treatment
WO2022182483A1 (en) * 2021-02-02 2022-09-01 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
JP2025525451A (ja) * 2022-06-30 2025-08-05 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ Cd25特異的抗体およびその使用
CN120584138A (zh) * 2023-02-06 2025-09-02 豪夫迈·罗氏有限公司 组合疗法及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013009475A1 (en) * 2011-07-11 2013-01-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Photosensitizing antibody-phuorophore conjugates
CA2954463C (en) * 2014-08-08 2023-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
CN121270700A (zh) * 2015-08-07 2026-01-06 美国政府(由卫生和人类服务部的部长所代表) 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit)
ES2992591T3 (en) * 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
CN109863346A (zh) 2016-10-25 2019-06-07 乐天医药生技股份有限公司 用于光免疫治疗的光漫射装置
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
WO2019199751A1 (en) * 2018-04-10 2019-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation

Similar Documents

Publication Publication Date Title
Malik et al. Futuristic approach to cancer treatment
JP2014132009A5 (cg-RX-API-DMAC10.html)
JP2012500180A5 (cg-RX-API-DMAC10.html)
JP7627259B2 (ja) 抗cd25抗体-フタロシアニン色素コンジュゲートおよび抗pd1抗体を使用したがんの処置のための近赤外(nir)光免疫療法(pit)
WO2021182573A1 (ja) 癌の治療及び/又は予防のための医薬品
Hallqvist et al. Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial
JP2023505222A5 (cg-RX-API-DMAC10.html)
JP2021505571A (ja) 末梢t細胞リンパ腫および皮膚t細胞リンパ腫を治療するための組成物および方法
EP4119557A1 (en) Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound
JP2025163103A (ja) 放射線および/または抗がん治療補助療法としてアデノシン二リン酸リボースの活用
Serre et al. Brachytherapy: Perspectives for combined treatments with immunotherapy
Larkin Investigational RSV vaccine given during pregnancy protects newborns
Chambial et al. Conventional methods of cancer therapy
Lan et al. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers
WO2021182571A1 (ja) 癌の治療及び/又は予防のための医薬品
Cerbon et al. Abscopal effect observed in visceral and osseous metastases after liver SBRT in combination with nivolumab and relatlimab for sinonasal mucosal melanoma—a case report
Chen et al. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: A clinical phase II trial
RU2123827C1 (ru) Способ лечения злокачественных опухолей
Peng et al. Tumor therapeutic modes
South-East European Oncology Group (SEEOG) et al. Phase II study of 4′-epi-doxorubicin in patients with untreated, extensive small cell lung cancer
CN111773388B (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
US20190015393A1 (en) The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse
JP2019513826A (ja) 放射線療法の改善
Carney et al. Etoposide in the treatment of elderly/poor-prognosis patients with small-cell lung cancer
Jorge Ignacio et al. The Genevieve Protocol: Phase I/II evaluation of a dual targeted approach to cancer gene therapy/immunotherapy